NILOTINIB 400 MG BID DAILY AS FRONTLINE THERAPY OF PH plus CHRONIC MYELOID LEUKEMIA: DOSE DELIVERY AND SAFETY PROFILE AT 2 YEARS

被引：0
|
作者：
Castagnetti, F. [1 ]
Palandri, F. [1 ]
Breccia, M. [2 ]
Levato, L. [3 ]
Capucci, A. [4 ]
Tiribelli, M. [5 ]
Zaccaria, A. [6 ]
Bocchia, M. [7 ]
Cuneo, A. [8 ]
Stagno, F. [9 ]
Specchia, G. [10 ]
Musso, M. [11 ]
Gugliotta, G. [1 ]
Testoni, N. [1 ]
Alimena, G. [2 ]
Pane, F. [12 ]
Martinelli, G. [1 ]
Saglio, G. [13 ]
Baccarani, M. [1 ]
Rosti, G. [1 ]
机构：
[1] Univ Bologna, Dpt Hematol & Oncol Seragnoli, Bologna, Italy
[2] Univ Roma La Sapienza, Dept Biotechnol & Hematol, Rome, Italy
[3] A Pugliese Hosp, Hematol Unit, Catanzaro, Italy
[4] Spedali Civil Brescia, Hematol Unit, I-25125 Brescia, Italy
[5] Univ Udine, Dept Med & Morphol Res, I-33100 Udine, Italy
[6] Ravenna Hosp, Hematol Unit, Ravena, Italy
[7] Univ Siena, Dept Hematol, I-53100 Siena, Italy
[8] Univ Ferrara, Dept Hematol, I-44100 Ferrara, Italy
[9] Univ Catania, Dept Biomed Sci, Catania, Italy
[10] Univ Bari, Dept Hematol, Bari, Italy
[11] La Madalena Hosp, Hematol & Bone Marrow Transplantat Unit, Palermo, Italy
[12] Univ Naples Federico II, Dept Biochem & Med Biotechnol, Naples, Italy
[13] Univ Turin, Dpt Clin & Biol Sci, Orbassano, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0814
引用
收藏
页码：340 / 341
页数：2
相关论文
共 50 条
  • [1] Nilotinib 800 Mg Daily as Frontline Therapy of Ph plus Chronic Myeloid Leukemia: Dose Delivered and Safety Profile for the GIMEMA CML Working Party
    Rosti, Gianantonio
    Castagnetti, Fausto
    Palandri, Francesca
    Breccia, Massimo
    Levato, Luciano
    Gugliotta, Gabriele
    Capucci, Adele
    Cedrone, Michele
    Fava, Carmen
    Intermesoli, Tamara
    Cambrin, Giovanna Rege
    Stagno, Fabio
    Tiribelli, Mario
    Amabile, Marilina
    Luatti, Simona
    Poerio, Angela
    Soverini, Simona
    Testoni, Nicoletta
    Alimena, Giuliana
    Pane, Fabrizio
    Saglio, Giuseppe
    Baccarani, Michele
    Martinelli, Giovanni
    BLOOD, 2009, 114 (22) : 868 - 868
  • [2] NILOTINIB 400 MG BID IN EARLY CHRONIC PHASE PH plus CHRONIC MYELOID LEUKEMIA: RESULTS AT 2 YEARS OF A PHASE II TRIAL
    Rosti, G.
    Castagnetti, F.
    Palandri, F.
    Poerio, A.
    Breccia, M.
    Levato, L.
    Capucci, A.
    Tiribelli, M.
    Zaccaria, A.
    Intermesoli, T.
    Martino, B.
    Cedrone, M.
    Gugliotta, G.
    Amabile, M.
    Testoni, N.
    Alimena, G.
    Pane, F.
    Saglio, G.
    Martinelli, G.
    Baccarani, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 459 - 459
  • [3] Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph plus Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party
    Castag-Netti, Fausto
    Rosti, Gianantonio
    Breccia, Massimo
    Gozzini, Antonella
    Stagno, Fabio
    Cambrin, Giovanna Rege
    Pierri, Ivana
    Luciano, Luigia
    Specchia, Giorgina
    Abruzzese, Elisabetta
    Martino, Bruno
    Capucci, Adele
    Bocchia, Monica
    Cavazzini, Francesco
    Tiribelli, Mario
    Gugliotta, Gabriele
    Palandri, Francesca
    Durante, Sandra
    Soverini, Simona
    Testoni, Nicoletta
    Pane, Fabrizio
    Saglio, Giuseppe
    Alimena, Giuliana
    Martinelli, Giovanni
    Baccarani, Michele
    BLOOD, 2011, 118 (21) : 209 - 210
  • [4] Efficacy and safety of nilotinib 800 mg daily in early chronic phase Ph plus chronic myeloid leukemia: Results of a phase II trial at 2 years.
    Rosti, G.
    Castagnetti, F.
    Palandri, F.
    Poerio, A.
    Soverini, S.
    Breccia, M.
    Pane, F.
    Martinelli, G.
    Baccarani, A.
    Saglio, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] FRONTLINE TREATMENT OF PHILADELPHIA POSITIVE CHRONIC MYELOID LEUKEMIA WITH SEQUENTIAL ADMINISTRATION OF NILOTINIB 400 MG TWICE DAILY AND IMATINIB 400 MG ONCE DAILY: A PHASE 2 MULTICENTRIC STUDY
    Castagnetti, F.
    Rosti, G.
    Breccia, M.
    Stagno, F.
    Gozzini, A.
    Specchia, G.
    Capucci, A.
    Martino, B.
    Cambrin, G. Rege
    Luciano, L.
    Abruzzese, E.
    Bocchia, M.
    Cavazzini, F.
    Tiribelli, M.
    Pierri, I.
    Gugliotta, G.
    Palandri, F.
    Durante, S.
    Soverini, S.
    Testoni, N.
    Pane, F.
    Saglio, G.
    Alimena, G.
    Martinelli, G.
    Baccarani, M.
    HAEMATOLOGICA, 2012, 97 : 238 - 238
  • [6] Results From the ENESTnd Extension Study: Efficacy and Safety of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP), Treated with Nilotinib 400 Mg Twice Daily (BID) After Suboptimal Response (SoR) or Treatment Failure (TF) to Imatinib 400 Mg Once Daily (QD) or Nilotinib 300 Mg BID
    Hochhaus, Andreas
    Ossenkoppele, Gert
    Reiffers, Josy
    Yao, Ming
    Shibayama, Hirohiko
    Gatterman, Norbert
    Hughes, Timothy P.
    Saglio, Giuseppe
    Larson, Richard A.
    Hoenekopp, Albert
    Gallagher, Neil J.
    Yu, Richard
    Blakesley, Rick E.
    Lobo, Clarisse
    Kantarjian, Hagop M.
    BLOOD, 2011, 118 (21) : 55 - 56
  • [7] LONG-TERM OUTCOME OF ALTERNATING NILOTINIB 400 MG TWICE DAILY AND IMATINIB 400 MG ONCE DAILY AS FRONTLINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: A PHASE 2 STUDY OF THE GIMEMA CML WORKING PARTY
    Gugliotta, G.
    Castagnetti, F.
    Breccia, M.
    Gozzini, A.
    Stagno, F.
    Rege-Cambrin, G.
    Carella, A. M.
    Luciano, L.
    Abruzzese, E.
    Martino, B.
    Usala, E.
    Rossi, G.
    Bocchia, M.
    Cavazzini, F.
    Tiribelli, M.
    Luatti, S.
    Venturi, C.
    Soverini, S.
    Cavo, M.
    Specchia, G.
    Alimena, G.
    Pane, F.
    Martinelli, G.
    Saglio, G.
    Rosti, G.
    Baccarani, M.
    HAEMATOLOGICA, 2015, 100 : 131 - 131
  • [8] Nilotinib as frontline therapy for patients with newly diagnosed Ph plus chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd
    Nakamae, Hirohisa
    Shibayama, Hirohiko
    Kurokawa, Mineo
    Fukuda, Tetsuya
    Nakaseko, Chiaki
    Kanda, Yoshinobu
    Nagai, Tadashi
    Ohnishi, Kazunori
    Maeda, Yasuhiro
    Matsuda, Akira
    Amagasaki, Taro
    Yanada, Masamitsu
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2011, 93 (05) : 624 - 632
  • [9] A prospective study of imatinib 400 mg vs 800 mg frontline in high risk Ph plus chronic myeloid leukemia (CML) patients
    Baccarani, Michele
    Castagnetti, Fausto
    Porkka, Kimmo
    Nielsen, Johan L.
    Hjorth-Hansen, Henrik
    Haznedaroglu, Ibrahim
    Nagler, Amon
    Rege-Cambrin, Giovarma
    Specchia, Giorgina
    Amabile, Marilina
    Testoni, Nicoletta
    Palandri, Francesca
    Pane, Fabrizio
    Alimena, Giuliana
    Martinelli, Giovanni
    Rosti, Gianantonio
    Simonsson, Bengt
    BLOOD, 2007, 110 (11) : 16A - 16A
  • [10] Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily
    Hughes, Timothy P.
    Hochhaus, Andreas
    Kantarjian, Hagop M.
    Cervantes, Francisco
    Guilhot, Francois
    Niederwieser, Dietger
    le Coutre, Philipp D.
    Rosti, Gianantonio
    Ossenkoppele, Gert
    Lobo, Clarisse
    Shibayama, Hirohiko
    Fan, Xiaolin
    Menssen, Hans D.
    Kemp, Charisse
    Larson, Richard A.
    Saglio, Giuseppe
    HAEMATOLOGICA, 2014, 99 (07) : 1204 - 1211
12345